Systematic evaluation of clinical practice guidelines for pharmacogenomics

To systematically assess methodological quality of pharmacogenomics clinical practice guidelines. Guidelines published through 2017 were reviewed by at least three independent reviewers using the AGREE II instrument, which consists of 23 items grouped into 6 domains and 2 items representing an overa...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2018-06, Vol.19 (8), p.693-700
Main Authors: Beckett, Robert D, Kisor, David F, Smith, Thomas, Vonada, Brooke
Format: Article
Language:English
Subjects:
AGREE II
Chemotherapy
Clinical medicine
Clinical practice guidelines
Collaboration
Consortia
Decision making
Drug dosages
Evidence-Based Medicine - standards
evidence-based practice
Fractures
Genomes
Health care
Humans
Oncology
Pharmacists
Pharmacogenetics - standards
Pharmacogenomics
Quality
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To systematically assess methodological quality of pharmacogenomics clinical practice guidelines. Guidelines published through 2017 were reviewed by at least three independent reviewers using the AGREE II instrument, which consists of 23 items grouped into 6 domains and 2 items representing an overall assessment. Items were assessed on a 7-point rating scale, and aggregate quality scores were calculated. Thirty-one articles were included. All guidelines were published as peer-reviewed articles and 90% (n = 28) were endorsed by professional organizations. Mean AGREE II domain scores (maximum score 100%) ranged from 46.6 ± 11.5% ('applicability') to 78.9 ± 11.4% ('Clarity of Presentation'). Median overall quality score was 72.2% (IQR: 61.1-77.8%). Quality of pharmacogenomics guidelines was generally high, but variable, for most AGREE II domains.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2018-0024